Navigation Links
Scientists sequence genome of parasite responsible for common sexually transmitted infection

Researchers have decoded the genetic makeup of the parasite that causes trichomoniasis, one of the most common sexually transmitted infections (STIs), revealing potential clues as to why the parasite has become increasingly drug resistant and suggesting possible pathways for new treatments, diagnostics and a potential vaccine strategy. The genome sequencing project, funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), is detailed in the January 12 issue of Science.

"The progress that continues to be made in deciphering the genomes of organisms, such as the Trichomonas vaginalis parasite, helps to further our collective scientific understanding of these organisms, so that we can better address public health issues," says NIH Director Elias A. Zerhouni, M.D.

"By better understanding the genetic makeup of the Trichomonas vaginalis parasite that causes trichomoniasis, we can target our efforts to developing the most effective medicines to treat the infection and potentially create a way to prevent infection altogether," says NIAID Director Anthony S. Fauci, M.D.

Trichomoniasis is a sexually transmitted infection that affects both men and women and results in roughly 7.4 million new cases in the United States each year, according to the U.S. Centers for Disease Control and Prevention.

In women, trichomoniasis infection commonly occurs in the vagina, resulting in heavy yellow-green or gray vaginal discharge, vaginal odor, discomfort during sexual intercourse and urination, irritation and itching of the genital area and, in rare cases, lower abdominal pain. In men, trichomoniasis is most common in the urethra; however, infected men often do not have symptoms. Those that do may experience irritation inside the penis, mild discharge, or a slight burning sensation after urination or ejaculation. Symptoms in both men and women generally appear within five to 28 days of
'"/>

Source:NIH/National Institute of Allergy and Infectious Diseases


Page: 1 2 3

Related biology news :

1. Scientists ID molecular switch in liver that triggers harmful effects of saturated and trans fats
2. Scientists Replicate Hepatitis C Virus in Laboratory
3. Scientists detect probable genetic cause of some Parkinsons disease cases
4. Scientists find missing enzyme for tuberculosis iron scavenging pathway
5. Scientists seek answers on what activates deadly anthrax spores
6. Yale Scientists Find MicroRNA Regulates Ras Cancer Gene
7. Scientists collaborate to assess health of global environment
8. Scientists decipher genome of fungus that can cause life-threatening infections
9. Scientists discover the cellular roots of graying hair
10. Scientists rid stem cell culture of key animal cells
11. Scientists develop new color-coded test for protein folding

Post Your Comments:
(Date:11/9/2009)...led phytoplankton are flourishing in areas of open...g of ice shelves and glaciers around the Antarctic... a beneficial impact on climate change. As the blo...ere it can store carbon for thousands or millions ... Global Change Biology , scientists from British A...
(Date:11/9/2009)...s David Queller and Joan Strassmann argue in a new...een components, from the genetic level on up, give...thing is an animal, a plant, a bacteria or a colo...ibe an organism, such as individuality or even mem...to achieve organismality. What is necessary, they ...
(Date:11/9/2009)...ire/ -- Genencor, a division of Danisco, has won t...erican Institute of Chemical Engineers (AIChE) for...losic ethanol. Yesterday, Robert Davis, Chair of t...Landon Steele, who is Marketing Director, Biomass ... Aaron Kelley, who is Senior Engineer, Biomass App...
Breaking Biology News(10 mins):Antarctica glacier retreat creates new carbon dioxide store 2What is the meaning of 'one'? 2What is the meaning of 'one'? 3Genencor Wins The American Institute of Chemical Engineers (AIChE) Sustainable Energy Award For Accellerase(R) Cellulosic Ethanol Enzymes 2UD to host conference on Ethics of Climate Change 10413 1UD to host conference on Ethics of Climate Change 10413 2CDPHP Launches National Network and Three In One Plan and Expands Member Incentives 59754 1CDPHP Launches National Network and Three In One Plan and Expands Member Incentives 59754 2CDPHP Launches National Network and Three In One Plan and Expands Member Incentives 59754 3CDPHP Launches National Network and Three In One Plan and Expands Member Incentives 59754 4Scientists Find New Key to Lupus 59752 1Scientists Find New Key to Lupus 59752 2
...izes and shapes, making them the perfect subject t...er is "rapidly becoming the standard for fruit mor...y led by Marin Talbot Brewer of The Ohio State Uni...nce. Details of the team,s latest Tomato Analyzer ...Journal of the American Society for Horticultural ...
...dustry has been growing rapidly since the mid-1980...onomy annually. Examples of nontimber forest produ..., medicinal and herbal products, and specialty flo... industry include U.S.-grown herbs used to satisfy.... American ginseng, for example, accounted for $32...
...chers have identified a new anticonvulsant compoun...f epilepsy. The findings are published in the Marc...arch discovery builds on previous work identifying...vity is associated with seizure disorders, a potas... found a new anticonvulsant compound that eliminat...
Other Biology News:New and improved tomato analyzer 2Decreasing deer damage 2Decreasing deer damage 3Drug prevents seizure progression in model of epilepsy 2
(Date:11/6/2009)...rstCall/ -- Helix BioPharma Corp. (TSX, FSE: "HBP"...ocherty, president and chief operating officer, wi...vestor Summit on November 10, 2009 at 4:00 PM at t...ill provide an overview of the Company,s leading p...terferon Alpha-2b. The slide show portion of the ...
(Date:11/6/2009)...FirstCall/ -- ,, 3Q09 Corporate Highlights: ...rketing Authorization to Astellas Pharma Europe Lt...ness activities Expanded management team to inclu...tor, Commercial Operations Appointed Bradford S. ...hairman , Upcoming 2009 Milestones: ,,...
(Date:11/6/2009)...- Intarcia Therapeutics, Inc. delivered two presen...ous delivery of exenatide) program for the treatme... Technology Meeting in San Francisco, CA: ,, (L.../SFTU126LOGO ) ,, Continuous Subcutaneous Del...ose, HbA1c and Reduces Weight in a 28-day Phase 1b...
(Date:11/5/2009)...FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC ) today ...ter ended September 30, 2009. GenVec reported a ne...hree months ended September 30, 2009 compared to a... comparable quarter of 2008. For the nine months e....1 million ($0.15 per share), compared to a net lo...
Breaking Biology Technology:Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 2Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 3NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6
... Phase 2 Switching Study, CRANBURY, N.J., March 1...y developing small-molecule, orally administered,p...an genetic diseases,announced today that the Compa...inical study of Plicera(TM) (isofagomine tartrate)...dical Genetics (ACMG) Annual Meeting from,March 12...
...lished online today in Genome Research ( www.gen...ry conservation of the genes and pathways associat...cation of conserved aging-related genes in simple ...ion of similar genes playing a role in human aging...organisms experience aging, the underlying mechani...
...ar Net Income up 283.0%, SHANGHAI, China, March 1... (Cayman) Inc. (NYSE: WX ), the leading global ph...outsourcing company headquartered in,Shanghai, Chi...s for the,fourth quarter and full year ended Decem... Compared to the fourth quarter 2006 results, -- ...
Other Biology Technology:Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease 2Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease 3Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease 4Growing old together: Yeast, worms and people may age by similar mechanisms 2WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 2WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 4WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 5WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 6WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 7WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 8WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 9WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 10WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 11WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 12
Rabbit Anti-Mouse Junctophilin-4, C-Terminus Monoclonal Antibody, Unconjugated, Clone PADZMD.487 from Invitrogen
...PCR Cloning Kits are designed to speed up the PCR ...s, regardless of sequence or type of polymerase us...ding those that are difficult to clone by other PC...for potentially detrimental proteins can be cloned...
Mounting Medium from BioVision
GeneAmp High Fidelity PCR from Applied Biosystems
Biology Products: